- Home
- ARVN vs BME Comparison
ARVN vs BME Comparison
Compare ARVN & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- BME
- Stock Information
- Founded
- ARVN 2015
- BME 2005
- Country
- ARVN United States
- BME United States
- Employees
- ARVN N/A
- BME N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- BME Trusts Except Educational Religious and Charitable
- Sector
- ARVN Health Care
- BME Finance
- Exchange
- ARVN Nasdaq
- BME Nasdaq
- Market Cap
- ARVN 456.2M
- BME 462.3M
- IPO Year
- ARVN 2018
- BME N/A
- Fundamental
- Price
- ARVN $7.81
- BME $36.50
- Analyst Decision
- ARVN Buy
- BME
- Analyst Count
- ARVN 21
- BME 0
- Target Price
- ARVN $20.53
- BME N/A
- AVG Volume (30 Days)
- ARVN 1.8M
- BME 34.0K
- Earning Date
- ARVN 07-29-2025
- BME 01-01-0001
- Dividend Yield
- ARVN N/A
- BME 6.26%
- EPS Growth
- ARVN N/A
- BME N/A
- EPS
- ARVN N/A
- BME 1.44
- Revenue
- ARVN $426,900,000.00
- BME N/A
- Revenue This Year
- ARVN $7.57
- BME N/A
- Revenue Next Year
- ARVN N/A
- BME N/A
- P/E Ratio
- ARVN N/A
- BME $28.37
- Revenue Growth
- ARVN 498.74
- BME N/A
- 52 Week Low
- ARVN $5.90
- BME $35.53
- 52 Week High
- ARVN $34.11
- BME $43.20
- Technical
- Relative Strength Index (RSI)
- ARVN 54.65
- BME 53.16
- Support Level
- ARVN $7.58
- BME $36.31
- Resistance Level
- ARVN $8.31
- BME $37.02
- Average True Range (ATR)
- ARVN 0.39
- BME 0.38
- MACD
- ARVN 0.03
- BME 0.03
- Stochastic Oscillator
- ARVN 64.75
- BME 63.89
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.